市場調査レポート

商品コード

1654430

単球活性化試験の市場規模、シェア、動向分析レポート：製品別、供給源別、最終用途別、地域別、セグメント別予測、2025年～2030年

Monocyte Activation Test Market Size, Share & Trends Analysis Report By Product (MAT Kits, Reagents), By Source (PBMC Based, Cell Line Based), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

出版日: 2025年01月30日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF & Excel (Single User License)

USD 5,950 873,579円

レポートPDF及びExcelを1名様のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷はできません。

Printable PDF & Excel (5-User License)

USD 6,950 1,020,399円

レポートPDF及びExcelを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。

Printable PDF & Excel (Enterprise License)

USD 8,950 1,314,039円

レポートの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF及びExcelのテキスト等のコピー＆ペースト、印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

単球活性化試験（MAT）市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の単球活性化試験市場規模は2025～2030年にかけて15.9％のCAGRを記録し、2030年には14億5,000万米ドルに達すると予測されています。

同市場は、いくつかの重要な要因によって牽引されています。動物実験をより倫理的でヒトに関連したin vitro手法に置き換える規制圧力の高まりが主要な促進要因です。ヒト免疫細胞を用いたMATの正確なパイロジェン検出能力は、従来のエンドトキシン試験に代わる魅力的な選択肢となっています。生物製剤、ワクチン、複雑な医薬品に対する需要の高まりは、これらの製品の安全性が極めて重要であることから、MATの採用をさらに後押ししています。さらに、バイオテクノロジーの進歩と、医薬品開発における患者の安全性と品質管理の重視の高まりが、市場の成長に寄与しています。

技術革新が単球活性化試験市場の成長を大きく後押ししています。主要開発のひとつは、より効率的で再現性の高い細胞培養システムの開発であり、特にTHP-1細胞やU937細胞のような不死化ヒト細胞株の使用が挙げられます。これらの細胞株は、MATの精度と一貫性を高め、従来の動物実験法に代わる、より信頼性の高い代替法となります。これらの細胞株を用いてヒトの免疫反応をシミュレートできるようになったことで、MATの感度が向上し、エンドトキシンと非エンドトキシンの両方を含むパイロジェン（発熱性物質）をより良好に検出できるようになりました。

もう一つの技術革新はMATプロセスの自動化であり、これによって試験ワークフローが合理化され、結果を得るのに必要な時間が短縮されました。MATサンプルの調製と分析のための自動化システムはスループットを向上させ、大規模な製薬企業やバイオテクノロジー企業が品質管理プロセスにMATを組み込むことをより現実的なものにしています。Minerva Biolabsの次世代MATシステムであるNAT-MATは、パイロジェン試験における大きな進歩を象徴しています。デジタルPCRを利用してIL-1BとTNF-aの遺伝子発現を測定することにより、NAT-MATは、エンドトキシンと非エンドトキシンの両方のパイロジェンを検出するための高感度で信頼性の高い結果を記載しています。このシステムは迅速な試験に最適化されており、Ph. Eur.2.6.30規格に準拠しています。

NAT-MAT（R）の主要革新点は、ハウスキーピング遺伝子と並行して2つのサイトカインを並行して測定することにあり、これにより結果の精度が向上します。ハウスキーピング遺伝子は、抽出プロセスと細胞密度の両方の品質管理として機能し、異なる細胞密度間でアッセイが確実に機能することを保証します。さらに、Minerva Biolabsの専用ソフトウェアによる自動分析は、プロセスを合理化し、試験効率を高めながら、規制要件へのコンプライアンスを保証します。

この技術は、医薬品やバイオテクノロジー製品の安全性を確保するためのより包括的で正確なアプローチを提供することで、従来のパイロジェン試験法よりも大幅に改善されます。例えば、ロンザ・グループやチャールズ・リバー・ラボラトリーズのような企業は、先進的細胞培養技術と自動化システムをMAT製品に統合し、効率性と拡大性を向上させています。さらに、高性能・スクリーニング技術の進歩により、より迅速で費用対効果の高いパイロジェン試験が可能になり、MATが医薬品開発やワクチン製造により広く利用されるようになっています。このような技術革新はMATの普及を促進し続け、医薬品やバイオテクノロジー製品の安全性と有効性を確保するための不可欠なツールとなっています。

単球活性化試験市場レポートハイライト

製品別では、MATキットセグメントが2024年に63.7%の最大売上シェアを占めました。MATキットセグメントは、信頼性の高いヒト関連パイロジェン試験法に対する需要の高まりにより成長を遂げています。主要促進要因は、動物実験を試験管内代替法に置き換える規制圧力の高まりです。MATキットは、エンドトキシンと非エンドトキシンパイロジェンを検出するためにヒト免疫細胞を使用することにより、正確で倫理的なソリューションを提供し、医薬品の安全性を確保します。さらに、生物製剤、ワクチン、複雑な薬剤製剤の普及率が上昇していることも、MATキットの需要を後押ししています。これらの製品は、市場に出回る前に厳格な安全性試験を行う必要があるからです。MATキットの利便性と精度は、その採用をさらに後押ししています。
動物実験に代わる、ヒトベースの倫理的な試験に対する需要の高まりにより、PBMCが市場を独占し、2024年には62.7%の最大シェアを占めました。単球を含むPBMCは、ヒトの免疫反応を忠実に模倣するため、発熱物質の検出には不可欠です。このヒトに関連した試験方法は、従来の動物モデルと比較して、より正確で再現性のある結果を提供できることから、支持を集めています。さらに、生物製剤開発、ワクチンの増加、動物実験を試験管内手法に置き換える規制当局の圧力が、PBMCベースのMAT試験の採用をさらに後押ししています。
用途別では、正確で信頼性の高いパイロジェン試験法に対する需要の高まりから、医薬品開発が市場を独占し、2024年には40.6%の最大シェアを占めました。製薬産業がより複雑な生物製剤やワクチンを開発するにつれ、厳格な試験によって製品の安全性を確保することが極めて重要になっています。MATは、従来の動物試験法に代わって、エンドトキシンや非エンドトキシンパイロゲンを検出するためのin vitroでヒトに関連したアプローチを記載しています。FDAやEMAなどの規制機関は、MATを有効な代替法として承認しており、医薬品開発におけるMATの採用をさらに促進しています。患者の安全性への関心の高まり、規制遵守、より迅速な試験手法の必要性が主要促進要因です。
最終用途別では、製薬産業セグメントが2024年に56.3%の最大市場シェアを占めています。医薬品開発・製造における信頼性の高いパイロジェン試験へのニーズの高まりなどが市場成長の原動力となっています。産業が生物製剤、ワクチン、その他の複雑な治療製品の製造に注力しているため、その安全性を確保することが最も重要です。ヒト免疫細胞を用いてエンドトキシンや非エンドトキシンのパイロジェンを検出できるMATは、従来の動物実験に代わる正確で倫理的な試験を記載しています。FDAやEMAのような規制機関はMATの使用を支持し、その採用を後押ししています。医薬品製造において、より安全で迅速かつ効率的な試験方法に対する需要が高まっていることが、MATの市場成長を促進する主要要因となっています。
北米が世界市場を席巻した主要要因は、この地域の厳しい規制環境にあり、FDAやカナダ保健省のような機関が、従来の動物実験に代わる信頼性が高く倫理的な方法としてMATを支持するようになってきています。MATの需要は、製品の安全性確保が極めて重要である生物製剤やワクチンセグメントの成長にも後押しされています。さらに、患者の安全性への関心の高まり、バイオテクノロジーの進歩、より効率的でヒトに関連したパイロジェン試験法の必要性が、北米におけるMATの広範な採用に寄与しています。
アジア太平洋は、2025～2030年までの予測期間においてCAGR 17.3%で最も急速な成長が見込まれており、製薬とバイオテクノロジーセグメントの急速な進歩が見られます。中国、日本、インドなどの国々における生物製剤、ワクチン、複合治療に対する需要の高まりが大きな要因です。これらの国の規制当局は、世界の倫理基準に沿って、従来の動物実験に代わる好ましい方法としてMATを採用するようになってきています。さらに、患者の安全性への関心の高まりと、より効率的でヒトに関連した試験方法の必要性が、MATの採用を促進しています。この地域の医療インフラの拡大は、MATの市場プレゼンス拡大をさらに後押ししています。

地域ダッシュボード
市場規模、予測動向分析、2018～2030年
北米
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- ノルウェー
- スウェーデン
- デンマーク
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- タイ
ラテンアメリカ
- ブラジル
- アルゼンチン
中東・アフリカ
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第9章競合情勢

主要市場参入企業による最近の動向と影響分析
企業/競合の分類
ベンダー情勢
- 主要販売代理店とチャネルパートナー一覧
- 主要企業の市場シェア分析、2024年
- Lonza Group
- Charles River Laboratories
- Bio-Rad Laboratories
- Seikagaku Corporation
- Hyglos GmbH
- Hyglos GmbH
- Thermo Fisher Scientific
- MAT BioTech
- Eurofins Scientific

図表

List of Tables

Table 1 List of abbreviation
Table 2 North America Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
Table 3 North America Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 4 North America Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 5 North America Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 6 North America Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 7 U.S. Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 8 U.S. Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 9 U.S. Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 10 U.S. Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 11 Canada Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 12 Canada Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 13 Canada Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 14 Canada Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 15 Mexico Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 16 Mexico Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 17 Mexico Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 18 Mexico Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 19 Europe Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
Table 20 Europe Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 21 Europe Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 22 Europe Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 23 Europe Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 24 Germany Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 25 Germany Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 26 Germany Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 27 Germany Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 28 UK Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 29 UK Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 30 UK Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 31 UK Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 32 France Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 33 France Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 34 France Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 35 France Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 36 Italy Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 37 Italy Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 38 Italy Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 39 Italy Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 40 Spain Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 41 Spain Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 42 Spain Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 43 Spain Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 44 Denmark Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 45 Denmark Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 46 Denmark Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 47 Denmark Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 48 Sweden Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 49 Sweden Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 50 Sweden Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 51 Sweden Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 52 Norway Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 53 Norway Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 54 Norway Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 55 Norway Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 56 Asia Pacific Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
Table 57 Asia Pacific Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 58 Asia Pacific Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 59 Asia Pacific Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 60 Aisa Pacific Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 61 China Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 62 China Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 63 China Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 64 China Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 65 Japan Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 66 Japan Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 67 Japan Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 68 Japan Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 69 India Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 70 India Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 71 India Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 72 India Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 73 South Korea Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 74 South Korea Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 75 South Korea Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 76 South Korea Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 77 Australia Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 78 Australia Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 79 Australia Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 80 Australia Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 81 Thailand Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 82 Thailand Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 83 Thailand Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 84 Thailand Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 85 Latin America Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
Table 86 Latin America Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 87 Latin America Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 88 Latin America Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 89 Latin America Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 90 Brazil Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 91 Brazil Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 92 Brazil Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 93 Brazil Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 94 Argentina Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 95 Argentina Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 96 Argentina Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 97 Argentina Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 98 MEA Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
Table 99 MEA Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 100 MEA Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 101 MEA Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 102 MEA Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 103 South Africa Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 104 South Africa Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 105 South Africa Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 106 South Africa Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 111 UAE Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 112 UAE Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 113 UAE Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 114 UAE Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
Table 115 Kuwait Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
Table 116 Kuwait Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
Table 117 Kuwait Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
Table 118 Kuwait Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Monocyte activation test (MAT) market: market outlook
Fig. 14 Monocyte activation test (MAT) competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Monocyte activation test (MAT) market driver impact
Fig. 18 Monocyte activation test (MAT) market restraint impact
Fig. 19 Monocyte activation test (MAT) market: Product movement analysis
Fig. 20 Monocyte activation test (MAT) market: Product outlook and key takeaways
Fig. 21 MAT Kits market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Reagents estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Monocyte activation test (MAT) market: Application movement analysis
Fig. 24 Monocyte activation test (MAT) market: Application outlook and key takeaways
Fig. 25 Drug Development market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Vaccine Development estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Medical Device Testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Others estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Monocyte activation test (MAT) market: Source movement analysis
Fig. 30 Monocyte activation test (MAT) market: Source outlook and key takeaways
Fig. 31 PBMC Based market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Cell Line Based estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Monocyte activation test (MAT) market: End use movement analysis
Fig. 34 Monocyte activation test (MAT) market: End use outlook and key takeaways
Fig. 35 Pharmaceutical Industry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Biotechnology Industry estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Medical Device Industry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Others estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Global Monocyte activation test (MAT) market: Regional movement analysis
Fig. 40 Global Monocyte activation test (MAT) market: Regional outlook and key takeaways
Fig. 41 Global Monocyte activation test (MAT) market share and leading players
Fig. 42 North America, by country
Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 U.S. key country dynamics
Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Canada key country dynamics
Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Mexico key country dynamics
Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 UK key country dynamics
Fig. 52 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Germany key country dynamics
Fig. 54 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 France key country dynamics
Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Italy key country dynamics
Fig. 58 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Spain key country dynamics
Fig. 60 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Denmark key country dynamics
Fig. 62 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Sweden key country dynamics
Fig. 64 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Norway key country dynamics
Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 China key country dynamics
Fig. 69 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Japan key country dynamics
Fig. 71 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 India key country dynamics
Fig. 73 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Thailand key country dynamics
Fig. 75 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 South Korea key country dynamics
Fig. 77 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Australia key country dynamics
Fig. 79 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Brazil key country dynamics
Fig. 82 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Argentina key country dynamics
Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 South Africa key country dynamics
Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Saudi Arabia key country dynamics
Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 UAE key country dynamics
Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Kuwait key country dynamics
Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Market share of key market players- Monocyte activation test (MAT) market

Product Code: GVR-4-68040-510-0

Monocyte Activation Test Market Growth & Trends:

The global monocyte activation test market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 15.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by several key factors. Increasing regulatory pressure to replace animal testing with more ethical, human-relevant in vitro methods is a major driver. MAT's ability to provide accurate pyrogen detection using human immune cells makes it an attractive alternative to traditional endotoxin tests. The growing demand for biologics, vaccines, and complex pharmaceuticals further fuels MAT adoption, as safety is critical in these products. Additionally, advancements in biotechnology and the increasing emphasis on patient safety and quality control in drug development are contributing to the market's growth.

Technological innovations are significantly driving the growth of the Monocyte Activation Test (MAT) market. One of the key advancements is the development of more efficient and reproducible cell culture systems, particularly the use of immortalized human cell lines like THP-1 and U937 cells. These cell lines enhance the accuracy and consistency of MAT, making it a more reliable alternative to traditional animal testing methods. The ability to simulate the human immune response with these cell lines has improved the sensitivity of MAT, allowing for better detection of pyrogens, including both endotoxins and non-endotoxins.

Another innovation is the automation of MAT processes, which has streamlined testing workflows and reduced the time required to obtain results. Automated systems for preparing and analyzing MAT samples have increased throughput, making it more feasible for large-scale pharmaceutical and biotechnology companies to incorporate MAT into their quality control processes. Minerva Biolabs' next-generation MAT system, the NAT-MAT, represents a significant advancement in pyrogen testing. By utilizing digital PCR to measure the gene expression of IL-1B and TNF-a, the NAT-MAT provides highly sensitive and reliable results for detecting both endotoxin and non-endotoxin pyrogens. This system is optimized for fast testing, making it suitable for in-process control and final release testing of medicinal products, in line with Ph. Eur. 2.6.30 standards.

The key innovation in the NAT-MAT(R) lies in the parallel measurement of two cytokines alongside a housekeeping gene, which improves the accuracy of results. The housekeeping gene serves a dual purpose: it acts as a quality control for both the extraction process and cell density, ensuring the assay functions reliably across different cell densities. Additionally, the automated analysis through Minerva Biolabs' specialized software streamlines the process, ensuring compliance with regulatory requirements while enhancing testing efficiency.

This technology provides a significant improvement over traditional pyrogen testing methods by offering a more comprehensive and precise approach to ensuring the safety of pharmaceutical and biotechnological products. For example, companies like Lonza Group and Charles River Laboratories have integrated advanced cell culture technologies and automated systems into their MAT offerings, improving efficiency and scalability. Furthermore, advancements in high-throughput screening technologies have enabled faster and more cost-effective pyrogen testing, allowing MAT to be used in drug development and vaccine production more widely. These technological innovations continue to enhance MAT's adoption, making it an essential tool for ensuring the safety and efficacy of pharmaceutical and biotechnological products.

Monocyte Activation Test Market Report Highlights:

Based on product, MAT Kits segment accounted for largest revenue share of 63.7% in 2024. The MAT Kits segment is experiencing growth due to the increasing demand for reliable, human-relevant pyrogen testing methods. A key driving factor is the growing regulatory pressure to replace animal testing with in vitro alternatives. MAT kits offer a precise and ethical solution by using human immune cells to detect endotoxins and non-endotoxin pyrogens, ensuring the safety of pharmaceutical products. Additionally, the rising prevalence of biologics, vaccines, and complex drug formulations is driving the demand for MAT kits, as these products require stringent safety testing before reaching the market. The convenience and accuracy of MAT kits further boost their adoption.
Based on source, PBMC dominated the market and accounted for the largest share of 62.7% in 2024, due to the increasing demand for human-based, ethical alternatives to animal testing. PBMCs, which include monocytes, are critical for detecting pyrogens as they closely mimic the human immune response. This human-relevant testing method is gaining favor due to its ability to provide more accurate and reproducible results compared to traditional animal models. Additionally, the rise in biologic drug development, vaccines, and regulatory pressures to replace animal testing with in vitro methods further drives the adoption of PBMC-based MAT testing.
Based on application, drug development dominated the market and accounted for the largest share of 40.6% in 2024, due to increasing demand for accurate and reliable pyrogen testing methods. As the pharmaceutical industry develops more complex biologics and vaccines, ensuring product safety through rigorous testing is crucial. MAT provides an in vitro, human-relevant approach to detect endotoxins and non-endotoxin pyrogens, replacing traditional animal testing methods. Regulatory bodies like the FDA and EMA endorse MAT as a valid alternative, further promoting its adoption in drug development. The growing focus on patient safety, regulatory compliance, and the need for faster testing methods are key driving factors.
Based on end use, pharmaceutical industry segment is dominated the end use segments with the largest market share of 56.3% in 2024. The market growth is fueled by factors such as increasing need for reliable pyrogen testing in drug development and manufacturing. As the industry focuses on producing biologics, vaccines, and other complex therapeutic products, ensuring their safety is paramount. MAT, with its ability to detect endotoxins and non-endotoxin pyrogens using human immune cells, provides an accurate and ethical alternative to traditional animal testing. Regulatory agencies like the FDA and EMA support MAT's use, driving its adoption. The growing demand for safer, faster, and more efficient testing methods in pharmaceutical production is a key factor fueling MAT's market growth.
North America dominated the global market, primary driver is the region's stringent regulatory environment, with agencies like the FDA and Health Canada increasingly endorsing MAT as a reliable and ethical alternative to traditional animal testing. The demand for MAT is also fueled by the growing biologics and vaccine sectors, where ensuring product safety is crucial. Additionally, the rising focus on patient safety, advancements in biotechnology, and the need for more efficient and human-relevant pyrogen testing methods are contributing to the widespread adoption of MAT in North America.
Asia Pacific region is expected to witness fastest growth with a CAGR of 17.3% over the forecast period from 2025 to 2030, rapid advancements in the pharmaceutical and biotechnology sectors. The growing demand for biologics, vaccines, and complex therapeutics in countries like China, Japan, and India is a major factor. Regulatory authorities in these countries are increasingly adopting MAT as a preferred alternative to traditional animal testing, aligning with global ethical standards. Additionally, the rising focus on patient safety and the need for more efficient, human-relevant testing methods are driving MAT adoption. The region's expanding healthcare infrastructure further supports MAT's growing market presence.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Source
- 1.2.3. Application
- 1.2.4. End-use
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Product and source outlook
- 2.2.2. Application and end use outlook
- 2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Monocyte activation test (MAT) Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Increasing demand for safer and more accurate alternatives to LAL (Limulus Amebocyte Lysate) test
  - 3.2.1.2. Rising regulatory requirements for medical devices and pharmaceuticals
  - 3.2.1.3. Growing adoption of in vitro testing methods
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High initial setup costs
  - 3.2.2.2. Limited standardization and adoption across all regulatory frameworks
3.3. Monocyte activation test (MAT) Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
- 3.3.3. Pricing Analysis

Chapter 4. Monocyte activation test (MAT) Market: Product Estimates & Trend Analysis

4.1. Global Monocyte activation test (MAT) Market: Product Dashboard
4.2. Global Monocyte activation test (MAT) Market: Product Movement Analysis
4.3. Global Monocyte activation test (MAT) Market by Product, Revenue
4.4. MAT Kits
- 4.4.1. MAT kits market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Reagents
- 4.5.1. Reagents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Monocyte activation test (MAT) Market: Application Estimates & Trend Analysis

5.1. Global Monocyte activation test (MAT) Market: Application Dashboard
5.2. Global Monocyte activation test (MAT) Market: Application Movement Analysis
5.3. Global Monocyte activation test (MAT) Market by Application , Revenue
5.4. Drug Development
- 5.4.1. Drug Development market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Vaccine Development
- 5.5.1. Vaccine Development market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Medical Device Testing
- 5.6.1. Medical Device Testing market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Others
- 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Monocyte activation test (MAT) Market: Source Estimates & Trend Analysis

6.1. Global Monocyte activation test (MAT) Market: Source Dashboard
6.2. Global Monocyte activation test (MAT) Market: Source Movement Analysis
6.3. Global Monocyte activation test (MAT) Market by Source, Revenue
6.4. PBMC Based
- 6.4.1. PBMC Based market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Cell Line Based
- 6.5.1. Cell Line Based market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Monocyte activation test (MAT) Market: End use Estimates & Trend Analysis

7.1. Global Monocyte activation test (MAT) Market: End use Dashboard
7.2. Global Monocyte activation test (MAT) Market: End use Movement Analysis
7.3. Global Monocyte activation test (MAT) Market by End use, Revenue
7.4. Pharmaceutical Industry
- 7.4.1. Pharmaceutical Industry market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Biotechnology Industry
- 7.5.1. Biotechnology Industry market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Medical Device Industry
- 7.6.1. Medical Device Industry Analysis market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Others
- 7.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Monocyte activation test (MAT) Market: Regional Estimates & Trend Analysis by Product, Source, Application and Methodology

8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
- 8.3.1. U.S.
  - 8.3.1.1. Key country dynamics
  - 8.3.1.2. Regulatory framework/ reimbursement structure
  - 8.3.1.3. Competitive scenario
  - 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.3.2. Canada
  - 8.3.2.1. Key country dynamics
  - 8.3.2.2. Regulatory framework/ reimbursement structure
  - 8.3.2.3. Competitive scenario
  - 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.3.3. Mexico
  - 8.3.3.1. Key country dynamics
  - 8.3.3.2. Regulatory framework/ reimbursement structure
  - 8.3.3.3. Competitive scenario
  - 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
- 8.4.1. UK
  - 8.4.1.1. Key country dynamics
  - 8.4.1.2. Regulatory framework/ reimbursement structure
  - 8.4.1.3. Competitive scenario
  - 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.2. Germany
  - 8.4.2.1. Key country dynamics
  - 8.4.2.2. Regulatory framework/ reimbursement structure
  - 8.4.2.3. Competitive scenario
  - 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.3. France
  - 8.4.3.1. Key country dynamics
  - 8.4.3.2. Regulatory framework/ reimbursement structure
  - 8.4.3.3. Competitive scenario
  - 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.4. Italy
  - 8.4.4.1. Key country dynamics
  - 8.4.4.2. Regulatory framework/ reimbursement structure
  - 8.4.4.3. Competitive scenario
  - 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.5. Spain
  - 8.4.5.1. Key country dynamics
  - 8.4.5.2. Regulatory framework/ reimbursement structure
  - 8.4.5.3. Competitive scenario
  - 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.6. Norway
  - 8.4.6.1. Key country dynamics
  - 8.4.6.2. Regulatory framework/ reimbursement structure
  - 8.4.6.3. Competitive scenario
  - 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.7. Sweden
  - 8.4.7.1. Key country dynamics
  - 8.4.7.2. Regulatory framework/ reimbursement structure
  - 8.4.7.3. Competitive scenario
  - 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.8. Denmark
  - 8.4.8.1. Key country dynamics
  - 8.4.8.2. Regulatory framework/ reimbursement structure
  - 8.4.8.3. Competitive scenario
  - 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
- 8.5.1. Japan
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Regulatory framework/ reimbursement structure
  - 8.5.1.3. Competitive scenario
  - 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. China
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework/ reimbursement structure
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. India
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Regulatory framework/ reimbursement structure
  - 8.5.3.3. Competitive scenario
  - 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.4. Australia
  - 8.5.4.1. Key country dynamics
  - 8.5.4.2. Regulatory framework/ reimbursement structure
  - 8.5.4.3. Competitive scenario
  - 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.5. South Korea
  - 8.5.5.1. Key country dynamics
  - 8.5.5.2. Regulatory framework/ reimbursement structure
  - 8.5.5.3. Competitive scenario
  - 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.6. Thailand
  - 8.5.6.1. Key country dynamics
  - 8.5.6.2. Regulatory framework/ reimbursement structure
  - 8.5.6.3. Competitive scenario
  - 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
- 8.6.1. Brazil
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Regulatory framework/ reimbursement structure
  - 8.6.1.3. Competitive scenario
  - 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.2. Argentina
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework/ reimbursement structure
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
- 8.7.1. South Africa
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Regulatory framework/ reimbursement structure
  - 8.7.1.3. Competitive scenario
  - 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.2. Saudi Arabia
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework/ reimbursement structure
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. UAE
  - 8.7.3.1. Key country dynamics
  - 8.7.3.2. Regulatory framework/ reimbursement structure
  - 8.7.3.3. Competitive scenario
  - 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.4. Kuwait
  - 8.7.4.1. Key country dynamics
  - 8.7.4.2. Regulatory framework/ reimbursement structure
  - 8.7.4.3. Competitive scenario
  - 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
- 9.3.1. List of key distributors and channel partners
- 9.3.2. Key customers
- 9.3.3. Key company market share analysis, 2024
- 9.3.4. Lonza Group
  - 9.3.4.1. Company overview
  - 9.3.4.2. Financial performance
  - 9.3.4.3. Product benchmarking
  - 9.3.4.4. Strategic initiatives
- 9.3.5. Charles River Laboratories
  - 9.3.5.1. Company overview
  - 9.3.5.2. Financial performance
  - 9.3.5.3. Product benchmarking
  - 9.3.5.4. Strategic initiatives
- 9.3.6. Bio-Rad Laboratories
  - 9.3.6.1. Company overview
  - 9.3.6.2. Financial performance
  - 9.3.6.3. Product benchmarking
  - 9.3.6.4. Strategic initiatives
- 9.3.7. Seikagaku Corporation
  - 9.3.7.1. Company overview
  - 9.3.7.2. Financial performance
  - 9.3.7.3. Product benchmarking
  - 9.3.7.4. Strategic initiatives
- 9.3.8. Hyglos GmbH
  - 9.3.8.1. Company overview
  - 9.3.8.2. Financial performance
  - 9.3.8.3. Product benchmarking
  - 9.3.8.4. Strategic initiatives
- 9.3.9. Hyglos GmbH
  - 9.3.9.1. Company overview
  - 9.3.9.2. Financial performance
  - 9.3.9.3. Product benchmarking
  - 9.3.9.4. Strategic initiatives
- 9.3.10. Thermo Fisher Scientific
  - 9.3.10.1. Company overview
  - 9.3.10.2. Financial performance
  - 9.3.10.3. Product benchmarking
  - 9.3.10.4. Strategic initiatives
- 9.3.11. MAT BioTech
  - 9.3.11.1. Company overview
  - 9.3.11.2. Financial performance
  - 9.3.11.3. Product benchmarking
  - 9.3.11.4. Strategic initiatives
- 9.3.12. Eurofins Scientific
  - 9.3.12.1. Company overview
  - 9.3.12.2. Financial performance
  - 9.3.12.3. Product benchmarking
  - 9.3.12.4. Strategic initiatives

単球活性化試験の市場規模、シェア、動向分析レポート：製品別、供給源別、最終用途別、地域別、セグメント別予測、2025年～2030年

Monocyte Activation Test Market Size, Share & Trends Analysis Report By Product (MAT Kits, Reagents), By Source (PBMC Based, Cell Line Based), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

単球活性化試験（MAT）市場の成長と動向

単球活性化試験市場レポートハイライト

目次

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章単球活性化試験市場の変数、動向、範囲

第4章単球活性化試験市場：製品別、推定・動向分析

第5章単球活性化試験市場：用途別、推定・動向分析

第6章単球活性化試験市場：供給源別、推定・動向分析

第7章単球活性化試験市場：最終用途別、推定・動向分析

第8章単球活性化試験市場：製品、供給源、用途、最終用途別、地域別、推定・動向分析

第9章競合情勢

List of Tables

List of Figures

Monocyte Activation Test Market Growth & Trends:

Monocyte Activation Test Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Monocyte activation test (MAT) Market Variables, Trends & Scope

Chapter 4. Monocyte activation test (MAT) Market: Product Estimates & Trend Analysis

Chapter 5. Monocyte activation test (MAT) Market: Application Estimates & Trend Analysis

Chapter 6. Monocyte activation test (MAT) Market: Source Estimates & Trend Analysis

Chapter 7. Monocyte activation test (MAT) Market: End use Estimates & Trend Analysis

Chapter 8. Monocyte activation test (MAT) Market: Regional Estimates & Trend Analysis by Product, Source, Application and Methodology

Chapter 9. Competitive Landscape

単球活性化試験の市場規模、シェア、動向分析レポート：製品別、供給源別、最終用途別、地域別、セグメント別予測、2025年～2030年

Monocyte Activation Test Market Size, Share & Trends Analysis Report By Product (MAT Kits, Reagents), By Source (PBMC Based, Cell Line Based), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

単球活性化試験（MAT）市場の成長と動向

単球活性化試験市場レポートハイライト

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 単球活性化試験市場の変数、動向、範囲

第4章 単球活性化試験市場：製品別、推定・動向分析

第5章 単球活性化試験市場：用途別、推定・動向分析

第6章 単球活性化試験市場：供給源別、推定・動向分析

第7章 単球活性化試験市場：最終用途別、推定・動向分析

第8章 単球活性化試験市場：製品、供給源、用途、最終用途別、地域別、推定・動向分析

第9章 競合情勢

List of Tables

List of Figures

Monocyte Activation Test Market Growth & Trends:

Monocyte Activation Test Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Monocyte activation test (MAT) Market Variables, Trends & Scope

Chapter 4. Monocyte activation test (MAT) Market: Product Estimates & Trend Analysis

Chapter 5. Monocyte activation test (MAT) Market: Application Estimates & Trend Analysis

Chapter 6. Monocyte activation test (MAT) Market: Source Estimates & Trend Analysis

Chapter 7. Monocyte activation test (MAT) Market: End use Estimates & Trend Analysis

Chapter 8. Monocyte activation test (MAT) Market: Regional Estimates & Trend Analysis by Product, Source, Application and Methodology

Chapter 9. Competitive Landscape

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章単球活性化試験市場の変数、動向、範囲

第4章単球活性化試験市場：製品別、推定・動向分析

第5章単球活性化試験市場：用途別、推定・動向分析

第6章単球活性化試験市場：供給源別、推定・動向分析

第7章単球活性化試験市場：最終用途別、推定・動向分析

第8章単球活性化試験市場：製品、供給源、用途、最終用途別、地域別、推定・動向分析

第9章競合情勢